Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18577216 | 0.98 | CA12 (0.43) | CA12CA7CA9CA14TSHR | |
| SCHEMBL16894217 | 0.84 | TSHR (0.40) | CA12CA7CA9CA14TSHR | |
| SCHEMBL20362833 | 0.82 | TSHR (0.41) | CA12CA7CA9CA14TSHR | |
| SCHEMBL11237051 | 0.82 | TET2 (0.39) | CA12CA7CA9CA14TSHR | |
| SCHEMBL21708634 | 0.82 | TET2 (0.39) | CA12CA7CA9CA14TSHR | |
| SCHEMBL3830166 | 0.80 | GAA (0.50) | TSHRCYP2C19CYP2D6MGAMGAA | |
| SCHEMBL21946049 | 0.79 | TSHR (0.40) | CA12CA7CA9CA14TSHR | |
| SCHEMBL73416 | 0.79 | TSHR (0.56) | CA12CA14TSHRTET2RECQL | |
| SCHEMBL5189416 | 0.79 | CYP2D6 (0.40) | CA12CA7CA14CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL15558552 | 0.78 | LMNA (0.35) | CA12CA7CA9CA14TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425450-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2024-12-26 | — | — | US | disclosed |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| EP-4210738-A2 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022056369-A2 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-9850276-B2 | Bidentate-binding modulators of LRRK2 and JNK kinases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850276-B2 | Bidentate-binding modulators of LRRK2 and JNK kinases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850276-B2 | Bidentate-binding modulators of LRRK2 and JNK kinases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2016-06-30 | — | — | US | disclosed |
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2016-06-30 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| WO-2008104756-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104756-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | disclosed |
| EP-1919864-A2 | FAP INHIBITORS | Ferring B.V. (NL) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| CN-1500080-A | Fused heterocyclic compounds | ����ҩƷ��ҵ��ʽ���� | 2004-05-26 | — | — | CN | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
| CN-1278790-A | Chemical compound | ASTRA ZENECA BRITISH INC (GB) | 2001-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | CA12 2329/4885CA7 650/4885CA9 829/4885 |
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | LRRK2, PINK1, MAP2K3 | CA12 4875/4885CA7 4874/4885CA9 3787/4885 |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | CA12 2787/4885CA7 3885/4885CA9 3009/4885 |
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | CA12 2226/4885CA7 703/4885CA9 304/4885 |
| US-20240425450-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | CA12 2787/4885CA7 3885/4885CA9 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.